In a report released today, Christian Ehmann from Warburg Research maintained a Buy rating on Fresenius SE & Co. KGaA (0OO9 – Research ...

Morgan Stanley raised the firm’s price target on Fresenius SE (FSNUY) to EUR 41 from EUR 40 and keeps an Overweight rating on the shares.

The healthcare company lifted its full-year guidance after a robust third quarter driven by Kabi and good organic growth at ...

Fresenius SE operates with an investment-grade credit profile, and Fresenius SE recently deconsolidated its position in Fresenius Medical Care, along with its debt. As of September 2024, Fresenius ...

Third Quarter 2024 Results Key Financial Results Revenue: €5.37b (up 3.5% from 3Q ...

DaVita’s strong services face risks from debt and economic uncertainties. Find out why DVA stock is a "Hold" with a $130 ...

Morgan Stanley raised the firm’s price target on Fresenius SE (FSNUY) to EUR 41 from EUR 40 and keeps an Overweight rating on the shares. TipRanks is the most comprehensive data set of sell side ...

Deutsche Bank raised the firm’s price target on Fresenius SE (FSNUY) to EUR 44 from EUR 42 and keeps a Buy rating on the shares. The views and opinions expressed herein are the views and ...

Narrow-moat Fresenius SE turned in strong third-quarter results helped by rising medical utilization, and management increased its 2024 outlook ranges. To account for recent cash flow generated ...

The presentation was e-mailed to our distribution list earlier today and is available on fresenius.com. On Slide 2 of the presentation, you'll find the usual safe harbor statement. Unless stated ...